Phosphoric Acid
CAS 7664-38-2
Phosphoric Acid (CAS 7664-38-2) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 108 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 33453.25 nM | 4 | - |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Creatinine renal clearance decreased | 66 | 172.656 | 10011372 |
| Sedation complication | 59 | 159.752 | 10079741 |
| Blood calcium decreased | 71 | 151.099 | 10005395 |
| Balance disorder | 102 | 138.374 | 10049848 |
| Skin candida | 32 | 130.09 | 10054152 |
| Orthostatic hypotension | 74 | 123.471 | 10031127 |
| Cognitive disorder | 76 | 107.941 | 10057668 |
| Sedation | 63 | 97.041 | 10039897 |
| Depressed level of consciousness | 75 | 93.173 | 10012373 |
| Constipation | 134 | 91.929 | 10010774 |
| Dehydration | 107 | 72.345 | 10012174 |
| Mobility decreased | 73 | 63.853 | 10048334 |
| Dysphagia | 71 | 62.549 | 10013950 |
| Neutropenic sepsis | 35 | 56.428 | 10049151 |
| Mucosal inflammation | 50 | 49.981 | 10028116 |
| Oesophagitis | 30 | 47.289 | 10030216 |
| Nervous system disorder | 32 | 46.074 | 10029202 |
| Gait disturbance | 80 | 43.133 | 10017577 |
| Mouth ulceration | 34 | 42.731 | 10028034 |
| Candida infection | 33 | 40.473 | 10074170 |
| Multiple drug therapy | 15 | 40.283 | 10074950 |
| Hypomagnesaemia | 34 | 40.26 | 10021027 |
| Hypotension | 113 | 39.647 | 10021097 |
| Fall | 125 | 38.548 | 10016173 |
| Hypokalaemia | 55 | 34.489 | 10021015 |
| Periarthritis | 12 | 31.946 | 10034464 |
| Radiation oesophagitis | 8 | 29.381 | 10048899 |
| Pain | 161 | 28.611 | 10033371 |
| Productive cough | 38 | 26.002 | 10036790 |
| Asthenia | 113 | 24.685 | 10003549 |
| Vomiting | 134 | 22.774 | 10047700 |
| Drug ineffective | 65 | 22.619 | 10013709 |
| Neutrophil count decreased | 36 | 22.282 | 10029366 |
| Nausea | 168 | 16.884 | 10028813 |
| Radiation pneumonitis | 8 | 16.314 | 10037765 |
| Diarrhoea | 156 | 15.919 | 10012735 |
| Off label use | 54 | 15.919 | 10053762 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| PHOSPHORIC ACID | 8259 | SU | MTHSPL |
| Phosphoric Acid | 8259 | SU | MTHSPL |
| Phosphoric acid | 8259 | SU | MTHSPL |
| phosphoric acid | 8259 | SU | MTHSPL |
| phosphoric acid | 8259 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Phosphoric Acid used for in pharmaceutical contexts?
Phosphoric Acid (CAS 7664-38-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Phosphoric Acid?
Phosphoric Acid has 108 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Creatinine renal clearance decreased, Sedation complication, Blood calcium decreased, Balance disorder, Skin candida. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Phosphoric Acid also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Phosphoric Acid with EU status "permitted".
What clinical phase is Phosphoric Acid in?
Phosphoric Acid is rendered with ChEMBL max phase 4 (approved).